Literature DB >> 1828096

Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.

H J Stellbrink1, H Albrecht, T Löning, H Greten.   

Abstract

The case of a 25-year-old homosexual man with large inguinal and perianal ulcers is reported. He had been pretreated extensively with acyclovir. Herpes simplex virus (HSV) was identified in the ulcer tissue by in-situ hybridization. No clinical improvement with acyclovir but a prompt response to foscarnet was noted. In a relapse after 11 weeks an acyclovir-resistant HSV type 2 was isolated. Again, a prompt response to foscarnet was noted. The case is presented in detail, and the clinical impact of resistance of HSV to acyclovir is discussed.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1828096     DOI： 10.1007/bf01666854

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  22 in total

1.  Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

Authors:  A Gateley; R M Gander; P C Johnson; S Kit; H Otsuka; S Kohl
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 2.  Viral tumor markers.

Authors:  T Löning; K Milde
Journal:  Curr Top Pathol       Date:  1987

3.  Acyclovir-resistant herpes in AIDS treated with foscarnet.

Authors:  M M Youle; D A Hawkins; P Collins; D C Shanson; R Evans; N Oliver; A Lawrence
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

4.  Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection.

Authors:  G J Mertz; L Eron; R Kaufman; L Goldberg; B Raab; M Conant; J Mills; T Kurtz; L G Davis
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir.

Authors:  N M Oliver; P Collins; J Van der Meer; J W Van't Wout
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

6.  In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme.

Authors:  J T Matthews; R D Carroll; J T Stevens; M L Haffey
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

Authors:  H J Field; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Treatment of resistant herpes simplex virus with continuous-infusion acyclovir.

Authors:  J P Engel; J A Englund; C V Fletcher; E L Hill
Journal:  JAMA       Date:  1990 Mar 23-30       Impact factor: 56.272

9.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

Authors:  F P Siegal; C Lopez; G S Hammer; A E Brown; S J Kornfeld; J Gold; J Hassett; S Z Hirschman; C Cunningham-Rundles; B R Adelsberg
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

10.  Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.

Authors:  K S Erlich; M A Jacobson; J E Koehler; S E Follansbee; D P Drennan; L Gooze; S Safrin; J Mills
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391
View more
  2 in total

1.  Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.

Authors:  Masayuki Saijo; Tatsuo Suzutani; Shigeru Morikawa; Ichiro Kurane
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 2.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.